Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London ...Middle East

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London )

Also on site :

• Occupation conducts military exercise on border with Jordan after completion of "Gilead" Division
• Numbrix 9 - June 30
• 21-year-old Baloch student becomes another victim of extrajudicial killing by Pakistani forces